Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NI 0801

Next Previous
Drug Profile

NI 0801

Alternative Names: Alpha-IP-10; EB 06; NI-0801; α-IP-10

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovImmune SA
  • Developer Edesa Biotech; NovImmune SA
  • Class Antiallergics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Chemokine CXCL10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome; Vitiligo
  • Discontinued Allergic contact dermatitis; Primary biliary cirrhosis

Most Recent Events

  • 14 May 2025 Edesa Biotech plans to file an IND application with the US FDA for Vitiligo in USA in second half of 2025
  • 14 May 2025 Edesa Biotech plans a phase II trial for Vitiligo in USA (IV)
  • 10 Jul 2023 Phase-II clinical trials in Vitiligo in Canada (IV) (Light Chain Bioscience pipeline, July 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top